One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

Desert Sun readers sound off on President Donald Trump, USAID, a Desert Sun longtime-columnist in today's letters to the ...

Disney is hosting a Hollywood premiere of “Snow White” on March 15, but the studio won’t be rolling out a robust red carpet ...

Peter Gaff’s column (“America is in trouble ... I met his partner, Steve, many years ago at a Lupus Support Group meeting as my daughter has Lupus and I wanted to gather information to share ...

To the ills of this world, Pope Francis calls us to be a Church that ministers to the body, mind and heart of our brothers ...

Peter? Thanks, Andrea ... our focus on expanding our base of business at academic medical centers and lupus centers. We've also targeted key rheumatology prescriber segments and identified ...

Officers, 10% owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks in the ...

Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%.

This followed last year’s restructuring, which included workforce reductions, to focus on lupus on autoimmune efforts ... Note that CEO Peter Greenleaf was among the officers selling shares.

Madelyn's, a Granville bakery that serves gluten-free and vegan treats, opened a wholesale kitchen and expanded its days of ...